Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia is a PHASE2 clinical asset sponsored by Hansoh BioMedical R&D Company in Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease. SEO and diligence focus: HS-20106, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.